EN






Science & Technology
Autoimmune
Pre-Clinical IND Clinical Research NDA Partner Available Rights
Stapokibart
CM310
IL-4Rα(mAb)
  • Moderate-to-severe AD--Adults
    Global
    ★CBTD granted by CDE ★Priority Review ★NDA Application
  • Moderate-to-severe AD--Children & Adolescents
    Global
  • CRSwNP
    Global
    ★Priority Review ★NDA Application
  • SAR
    Global
    ★NDA Application
  • Prurigo Nodularis
    Global
  • Moderate-to-severe eosinophilic asthma
    Global
  • COPD
    Global
CM326
TSLP(mAb)
  • CRSwNP
    Global ex mainland China
  • Moderate-to-severe asthma
    Global ex mainland China
  • COPD
    Global ex mainland China
CM512
  • Moderate-to-severe AD
    Greater China
CM313
CD38(mAb)
  • SLE
    Global
  • ITP
    Global
CM383
Aβ(mAb)
  • Alzheimer's Disease
    Global
Oncology
Pre-Clinical IND Clinical Research NDA Partner Available Rights
CMG901
Claudin 18.2
(ADC)
  • Gastric and Other Solid tumors
    ★FTD & ODD granted by FDA ★CBTD granted by CDE ★Global phase III clinical
CM313
CD38(mAb)
  • RRMM, lymphoma and other hematological malignancies
    Global
CM355
CD20xCD3
(Bispecific)
  • Lymphoma
    Global
CM336
BCMAxCD3
(Bispecific)
  • RRMM
    Global
CM350
GPC3xCD3
(Bispecific)
  • Solid tumors
    Global
CM380
GPRC5DxCD3(Bispecific)
  • RRMM
    Global
CM369
CCR8(mAb)
  • Tumors
    Global
Autoimmunity

The causes of autoimmune diseases are complex. Stimulated by specific antigens, the immune system will be repeatedly or excessively activated, resulting in increased cytokine secretion, mediated immune response attacking normal tissues, or callus formation through compensatory pathways, thus impairing normal physiological functions.

Relying on our own antibody discovery and drug evaluation platform, we have developed highly-effective blocking antibodies for different types of autoimmune diseases to effectively reduce effector cell- and cytokine-mediated inflammatory responses, and then to influence the disease progress and to improve the quality of life in patients.


Oncology

The treatment of malignant tumors has significantly developed  in recent years, especially the breakthrough of cancer immunotherapy. To further increase the clinical benefits to more patients and develop more effective treatment methods, we have cooperated with top domestic academic institutions and well-known companies in the industry to identify new targets, new mechanisms of action, and new combinations. At present, multiple molecules are in different stages of drug development.